Ocuphire Pharma Investor Day Presentation Deck
RM
Percent of Subjects (%)
56
MIRA-2: Gain of Visual Function (Accommodation)
Nyxol Demonstrates a Faster Return to Baseline Accommodation
Percent of Subjects with Unchanged Accommodation from Baseline
(Tropicamide or Paremyd)
Study Eye, PP population
Placebo (n=32) Nyxol (n=35)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
16%
11%
0
p=0.03
38%
60%
2
Time Post-Treatment with Nyxol/Placebo (Hours)
MIRA-2 Phase 3 Trial
Note: Worsening of accommodation was defined as an amplitude decrease of greater than 1 diopter
Source: MIRA-2 CSR table #14.2.3.2.1. PP population is the per protocol population.
Patel (2011). Pseudoaccommodation. International Ophthalmology Clinics, 51(2), 109-118.
●
●
●
Accommodation
Definition: Changing optical power to maintain a clear
image or focus on an object as the distance varies
Inhibition of the cholinergic system dilates the pupil
(mydriasis) and relaxes the ciliary muscle, which adjusts the
lens shape and thickness, worsening accommodation
(cycloplegia) and causing latent refractive errors to manifest
Mydriatic agents including Tropicamide and Paremyd inhibit
the cholinergic system; not seen with Phenylephrine
Nyxol
✓ Nyxol, a non-selective, alpha-1 antagonist, constricts the pupil
enhancing depth of focus by blocking unfocused peripheral light,
independent of the ciliary muscle
Ocuphire
PHARMAView entire presentation